Literature DB >> 11170962

Azithromycin and gentamicin therapy for the treatment of humans with brucellosis.

J Solera1, J L Beato, E Martínez-Alfaro, J C Segura, E de Tomas.   

Abstract

Ten patients with brucellosis were treated with azithromycin and gentamicin to assess the treatment's safety and efficacy. Seven patients had an excellent therapeutic response at the end of therapy; however, relapse was noted in 3. When relapse was considered in combination with an initial lack of efficacy, 5 patients (50%; 95% confidence interval, 18.7%-81.3%) did not respond to therapy; these results do not favor the use of azithromycin to treat brucellosis in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170962     DOI: 10.1086/318503

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Antimicrobial susceptibility of Brucella melitensis isolates in Peru.

Authors:  Ryan C Maves; Rosa Castillo; Alfredo Guillen; Benjamin Espinosa; Rina Meza; Nereyda Espinoza; Gladys Núñez; Luis Sánchez; Jesús Chacaltana; David Cepeda; Sofía González; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

2.  Penumonic presentation of brucellosis.

Authors:  Meenu Singh; Manju Salaria; Lata Kumar
Journal:  Indian J Pediatr       Date:  2005-01       Impact factor: 1.967

Review 3.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 4.  Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis.

Authors:  Julián Solís García del Pozo; Javier Solera
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

5.  Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.

Authors:  Javier Ariza; Mile Bosilkovski; Antonio Cascio; Juan D Colmenero; Michael J Corbel; Matthew E Falagas; Ziad A Memish; Mohammad Reza Hasanjani Roushan; Ethan Rubinstein; Nikolaos V Sipsas; Javier Solera; Edward J Young; Georgios Pappas
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.